Scrip
Avastin shows PFS benefit in third breast cancer trial but fails again to improve survival
11 June 2009
Malini Guha
Please Login to read the full article.
11 June 2009
Malini Guha
Roche's (Genentech) Avastin (bevacizumab) showed a progression-free survival (PFS) benefit in the Phase III first-line RIBBON-1 trial as in its two other Phase III trials in metastatic breast cancer, but as with them failed to demonstrate an overall survival benefit, with experts at the ASCO meeting...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Genentech files data with FDA to get full approval of Avastin in breast cancer
- Avastin meets endpoint in Phase III second-line breast cancer trial
- Pfizer faces disappointment with anticancers after more Phase III failures
- AstraZeneca's new anticancer Zactima fails to impress in lung cancer
COMMENT
Other Informa Comment
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
